Medical isotope developer IsoRay's cesium-131 seeds have been used for an application besides prostate cancer, the product's main clinical application, the Richland, WA-based company reported.
Tufts-New England Medical Center in Boston used the company's brachytherapy implants for cancer treatment of the eye in three patients on December 12. The cesium-131 brachytherapy seeds were attached to the surface of the patients' eyes over the area to be treated. They will be removed on December 17.
Cesium-131, a proprietary product of IsoRay, is marketed under the brand Proxcelan, and received U.S. Food and Drug Administration clearance in March 2003 for the treatment of soft-tissue cancers including prostate, eye, breast, brain, liver, and head and neck cancers. It has been used in over 1,900 prostate cancer brachytherapy procedures since October 2004, the company said.
Related Reading
IsoRay posts Q1 2008 results, November 9, 2007
IsoRay inks global alliance with Belgian firm, September 27, 2007
IsoRay expands new brachytherapy plant, August 30, 2007
IsoRay to join AMEX, April 16, 2007
IsoRay continues cesium-131 placements, April 5, 2007
Copyright © 2007 AuntMinnie.com
